LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...
LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food ...
Cabtreo combines clindamycin phosphate, a lincosamide antibacterial, adapalene, a retinoid, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic effects, into one topical gel.
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1% (USRLD: Cleocin T Gel, 1%). Clindamycin ...
LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that Pr CABTREO TM (clindamycin phosphate, adapalene and ...
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that ...
On Wednesday, September 20, the pharmaceutical company Zydus Lifesciences Ltd. announced that it has attained a critical milestone by receiving final approval from the US Food and Drug Administration ...